COLTENE Holding AG (LON:0QP7)
49.10
-1.40 (-2.77%)
At close: Aug 6, 2025
Acelyrin Revenue
COLTENE Holding AG had revenue of 118.05M CHF in the half year ending June 30, 2025, a decrease of -10.18%. This brings the company's revenue in the last twelve months to 240.71M, up 0.80% year-over-year. In the year 2024, COLTENE Holding AG had annual revenue of 250.16M with 3.06% growth.
Revenue (ttm)
240.71M CHF
Revenue Growth
+0.80%
P/S Ratio
1.23
Revenue / Employee
192.41K CHF
Employees
1,251
Market Cap
272.14M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 250.16M | 7.43M | 3.06% |
Dec 31, 2023 | 242.73M | -24.40M | -9.13% |
Dec 31, 2022 | 267.13M | -12.12M | -4.34% |
Dec 31, 2021 | 279.24M | 30.89M | 12.44% |
Dec 31, 2020 | 248.35M | -25.48M | -9.30% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |